Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix in IBD Patients on Vedolizumab
NCT03798691Phase 4Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2019
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Phase 4, open-label trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by University of Wisconsin–Madison. Primary endpoint: Cell Mediated Immunity. Started May 2019; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT03798691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798691.